TNF and inflammatory bowel disease: Neutralizing antibody titers, a key correlate of protection, were similarly affected with only 17% of IBD patients on anti-TNF therapies achieving neutralizing activities against SARS-CoV-2 Omicron BA.1 above threshold after basic immunization, compared to over 70% in both HCW groups and 65% in patients on ustekinumab/vedolizumab therapies.